Outcomes and costs of febrile neutropenia: Adventures in the science and art of treatment choices

Supportive Care in Cancer

Volumn 10, Issue 3, 2002, Pages 189-196

  Elting, Linda S ^a   Cantor, Scott B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cost and cost analysis; Cost effectiveness; Decision analysis; Febrile neutropenia; Outcomes

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INFECTION; MEDICAL DECISION MAKING; MORTALITY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

AMBULATORY CARE; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; FEVER; HOSPITALIZATION; HUMANS; NEOPLASMS; NEUTROPENIA; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0036943053     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200100300     Document Type: Review

References (55)

1. Aaronson NK, Beckmann JH (eds) (1987) The quality of life of cancer patients. Raven Press, New York
2. Anaissie EJ, Samonis G, Kalbakis K, Gorgoulias V (1997) Therapy of low-risk cancer patients with fever and neutropenia: Results of a prospective randomized trial with cost analysis (abstract LM51). Paper presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, 28 September to 1 October 1997
3. Balinksy W, Nesbitt S (1989) Cost-effectiveness of outpatient parenteral antibiotics: a review of the literature. Am J Med 87:301-305
4. Beam TR, Gilbert DN, Kunin CM (1992) General guidelines for the clinical evaluation of anti infective drug products. Clin Infect Dis 15 [Suppl 1]:5-32
5. Birnbaum HG, Tang M (1998) The home infusion therapy/relative benefit index - summary of an analysis using insurance claims data. Med Care 36:757-765
6. Bloom BS, Knorr RS, Evans AE (1985) The epidemiology of disease expenses - the costs of caring for children with cancer. JAMA 253:6
7. Bodey GP (1984) Antibiotics in patients with neutropenia. Arch Intern Med 144:1845-1851
8. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:2
9. Cantor SB, Rubenstein EB, Elting LS, Frisbee-Hume S, Bratka CS, Stedman D, Rolston KVI (1997) Economic evaluation of management strategies for low-risk febrile neutropenic cancer patients. J Clin Oncol 16:419a
10. Castagnola E, Paola D, Giacchino R, Rossi R, Viscoli C (1998) Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer. Support Care Cancer 6:524-528
11. Cella DF, Tulsky DS, Gray G, Sarafian B, Lloyd S, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, Eckberg K, Purl S, Blendowski C, Goodman M, Barnicle M, Steart I, McHale M, Bonomi P, Kaplan E, Taylor S, Thomas C, Harris J (1993) The functional assessment of cancer therapy (FACT) scale: Development and validation of the general measure. J Clin Oncol 11:570-579
12. Chaplin S (1991) Cancer therapy complications costly to treat. Hosp Doctor 9:30
13. Crawford, J, Ozer H, Stoller R, Johnson D, Lyman G, Tabarra I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahada A, Vincent M, Stewart M, Glaspy J (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170
14. Dranitsaris G, Tran MT, McGeer A, Narine L (1995) Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics 7:49-62
15. Eisenberg JM, Kitz DS (1986) Savings from outpatient antibiotic therapy for osteomyelitis - economic analysis of a therapeutic strategy. JAMA 255:12
16. Eisenberg JM, Koffer H, Finkler SA (1984) Economic analysis of a new drug: potential savings in hospital operating costs from the use of a once-daily regimen of a parenteral cephalosporin. Rev Infect Dis 6:S909-S923
17. Elliott CR, Pater JL (1988) The effect of different measures of outcome on the results of studies of empiric antibiotic therapy in febrile neutropenic patients. Clin Invest Med 11:327-330
18. Elting LS, Rubenstein EB, Rolston K, Cantor SB, Martin CG, Kurtin D, Rodriguez S, Lam T, Kanesan K, Bodey GP (2000) Time to clinical response: An outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol 18:3699-3706
19. Faulds D, Lewis NJW, Milne RJ (1992) Recombinant granulocyte colony-stimulating factor: Pharmacoeconomic considerations in chemotherapy-induced neutropenia. Pharmacoeconomics 1:231-249
20. Feld R (1993) Organization of clinical trials: Problems, controversies, definitions, and methodology related to infections in neutropenic patients. Recent Results Cancer Res 132:249-256
21. Feld R (1998) Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement? Support Care Cancer 6:444-448
22. Freifeld A, Marchigiani D, Walsh T, Canock S, Lewis L, Hiemenz J, Hiemenz S, Hicks JE, Gill V, Steinberg SM, Pizzo PA (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:5
23. Gardembas-Pain, Desablens B, Sensebe L, Lamy T, Ghandour C, Boasson M (1991) Home treatment of febrile neutropenia: An empirical oral antibiotic regimen. Ann Oncol 2:485-487
24. Gaynon PS, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Steinherz PG, Sensel MG, Lee MK, Stram DO, Sather HN (2001) Duration of hospitalization as a measure of cost on children's cancer group acute lymphoblastic leukemia studies. J Clin Oncol 19:1916-1925
25. Glaspy JA, Bleecker GC, Stoller RG, Strauss MJ (1991) Decreased costs in cancer chemotherapy patients using recombinant granulocyte colony-stimulating factor (abstract). Clin Res 39:7A
26. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
27. Gralla RJ, Eisenberg PD, Bizette GA (2000) Two outpatient oral trials using ciprofloxacin plus amoxicillin/clavulanate for febrile neutropenia in lower risk patients. Support Care Cancer 8:241
28. Hidalgo M, Homedo J (1999) Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 85:213-219
29. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KVI, Shenep JL, Young LS (1997) Guidelines from the Infectious Diseases Society of America: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25:551-73
30. Johnson JA, Bootman JL (1995) Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 155:1949-1956
31. Kane RE, Jennison K, Wood C, Black PG, Herbst JJ (1988) Cost savings and economic considerations using home intravenous antibiotic therapy for cystic fibrosis patients. Pediatr Pulmonol 4:84-89
32. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 341:312-318
33. Klastersky J, Zinner SH, Calandra T, Gaya H, Glauser MP, Meunier F, Rossi M, Schimpff SC, Tattersall M, Viscoli C, European Organization for Research and Treatment of Cancer Antimicrobial Therapy Cooperative Group (1978) Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer 24 [Suppl 1-D]:S35-S45
34. Kukull WA, Koepsell D, Conrad DA, Immanuel V, Prodzinski J, Franz C (1986) Rapid estimation of hospitalization charges from a brief medical record review. Med Care 24:10
35. Laupacis A, Feeny D, Detsky AS, et al (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluation. Can Med Assoc J 146:473-481
36. Leese B (1992) The costs of febrile neutropenia and the potential savings from G-CSF. Omnipress, Prague, pp 766-768
37. Leese B (1993) The costs of treating febrile neutropenia in six UK hospitals. Eur J Cancer [A] 29 [Suppl 7]:15-18
38. Leese B (1994) The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics 6:233-239
39. Malik IA, Khan WA, Aziz Z, Karim M (1994) Self-administered antibiotic therapy for chemotherapy- induced, low-risk febrile neutropenia in patients with non-hematologic neoplasms. Clin Infect Dis 19:522-527
40. Malik IA, Khan WA, Karim M, Aziz Z, Ata KM (1995) Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 98:224-231
41. Mullen CA, Buchanan GR (1990) Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient. J Clin Oncol 8:1998-2004
42. Neymark N (1998) Moving beyond acquisition cost reductionism. Support Care Cancer 6:488-489
43. Pater JL, Weir L (1986) Reporting the results of randomized trials of empiric antibiotics in febrile neutropenic patients - a critical survey. J Clin Oncol 4:346-352
44. Pizzo PA, Armstrong D, Bodey GP, de Pauw B, Feld R, Glauser M, Gaya H, Karp J, Klastersky J, Todeschini G, Verhoef J, Wade J, Young LS, Remington J (1990) The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 161:397-401
45. Rolston K, Rubenstein E, Elting L (1995) Ambulatory management of febrile episodes in low-risk neutropenic patients (abstract 2235). Programs and abstracts of the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, 1995, p 333
46. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, Hughes P, Moreland B, Fender A, Kennedy K, Holmes F, Elting LS, Bodey GP (1993) Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71:3640-3646
47. Schimpff S, Satterlee W, Young VM, Serpick A (1971) Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284:1061-1065
48. Schimpff SC (1985) Overview of empiric antibiotic therapy for the febrile neutropenic patient. Rev Infect Dis 7 [Suppl 4]:734-740
49. Smith TJ, Hillner BE, Desch CE (1993) Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J Natl Cancer Inst 85:1460-1474
50. Szucs TD (2001) Healthcare economic concepts in fever and neutropenia. In: Rolston KVI, Rubenstein EB (eds) Textbook of Febrile Neutropenia. Dunitz, London, pp 301-316
51. Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322
52. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R (1994) Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107-114
53. Viscoli C, Bruzzi P, Glauser M (1995) An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer [A] 31:2013-2022
54. Weinstein MC, Stason WB (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296:716-721
55. Winston DJ, Ho WG, Bruckner DA, Champlin RE (1991) Beta-lactam antibiotic therapy in febrile granulocytopenic patients. Ann Intern Med 115:849-859